Research protocols in the NICU

(Please click for more information on the protocol and inclusion/exclusion criteria)

Currently Enrolling

• Prematurity and Respiratory Outcomes Program (PROP) / IMproving Prematurity-related Respiratory Outcomes at Vanderbilt (IMPROV)

• Non-Invasive Inhaled Nitric Oxide in Premature Newborns

• Should very low birth weight infants receive nutrition during Indomethacin treatment for a patent ductus arteriosus? A multi-center randomized controlled trial

• Influence of altered cerebral spinal fluid and arterial flows on cerebral processing functions in premature infants with severe intraventricular hemorrhage

• Pilot Study of Head-Cooling in Preterm Infants with Hypoxic Ischemic Encephalopathy

• Use of Omega-3 Fat Emulsion (Omegaven) in Infants with Parenteral Nutrition Associated Liver Disease

Enrollment Complete with Follow-up Continuing

• Brain Manganese Deposition in High Risk Neonates

Completed Trials

• Impact of Neonatal Heart Rate Characteristics (HeRO)

• Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 days) with Suspected or Complicated Intra-Abdominal Infections

• Probiotic Administration for the Prevention of Death and Nosocomial Sepsis in Preterm Infants

• IV Levetiracetam (Keppra) Study

• Inhaled NO for the Prevention of Chronic Lung Disease

• Brain-Cooling For the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy Continued Access Protocol

• A 7-Day, Open Label, Multicenter, Pharmacokinetic Study (Part 1) Followed by A 7-Day, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study (Part 2) of IV Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension of the Newborn (PPHN) or Hypoxic Respiratory Failure and at Risk for PPHN” (Protocol A1481157 Pfizer, Inc)

• Identifying the Causes of and Decreasing the Incidence of Prematurity in High Risk Populations

• A randomized, double-blind, placebo controlled trial to assess the tolerability and efficacy of Lucinactant (Surfaxin®) in very low birth weight infants at risk for developing bronchopulmonary dysplasia

• Pantoprazole Delayed Released Granules for GERD

• A randomized, double-blind, placebo controlled trial to assess the tolerability and efficacy of Lucinactant (Surfaxin®) in very low birth weight infants at risk for developing bronchopulmonary dysplasia